Previous studies demonstrated that overexpression of angiotensinogen (AGT) in adipose tissue increased blood pressure. However, the contribution of endogenous AGT in adipocytes to the systemic renin-angiotensin system (RAS) and blood pressure control is undefined. To define a role of adipocyte-derived AGT, mice with loxP sites flanking exon 2 of the AGT gene (Agt 
INTRODUCTION
The renin angiotensin system (RAS) plays a major role in control of blood pressure. Angiotensinogen (AGT) is the only known precursor for production of angiotensin II (AngII). Angiotensin II increases blood pressure by increasing peripheral vascular resistance, increasing sympathetic nervous system activity, and through the control of sodium homeostasis. While the systemic RAS is recognized as an important endocrine system for blood pressure control, local production of AngII by various cell types and/or tissues has also been implicated in the pathophysiology of hypertension.
In 1994, Tanimoto and colleagues (35) demonstrated that mice with whole body deficiency of AGT had marked decreases of systemic concentrations of AGT and blood pressure (by 34 mmHg). These results demonstrated a primary role for AGT in the systemic RAS and blood pressure control. It is generally accepted that liver hepatocytes serve as a primary source for systemic AGT concentrations as the substrate for systemic concentrations of AngII. Previous studies demonstrated that adipose tissue is a major extra-hepatic source of AGT (2, 3, 5, 8) . Angiotensinogen is also expressed in several other extra-hepatic peripheral tissues, including kidney, adrenal, and brain (3, 8) . Further studies demonstrated that adipose tissue possesses each component necessary for the production of AngII from AGT, including renin-like activity (13, 21, 27, 30, 32) and angiotensin converting enzyme (ACE).
Given that adipocytes express high levels of AGT mRNA, it is conceivable that adipocyte-derived AGT contributes to plasma AGT concentrations and blood pressure control. In mice with targeted overexpression of AGT in adipose tissue, increases were observed in plasma AGT concentrations (22 to 44%) and blood pressure (16) .
Moreover, transgenic expression of AGT in adipose tissue of mice with whole body AGT deficiency modestly increased plasma AGT concentrations and partially restored blood pressure. These results were the first to suggest that adipocyte-derived AGT could modulate the systemic RAS; however, the contribution of endogenous AGT production by adipocytes to the systemic RAS and blood pressure control has not been defined.
In this study, to define the role of adipocyte-derived AGT to the systemic RAS and blood pressure control, mice with loxP sites flanking exon 2 of the AGT gene were bred to mice expressing an adipocyte fatty acid binding protein 4 promoter (aP2)-driven transgenic Cre recombinase to create mice with specific deletion of AGT in adipocytes.
To define the role of adipocyte-derived AGT to the systemic RAS and blood pressure control, we examined age-dependent effects of adipocyte AGT deficiency in male and female mice. Two months of age was chosen to represent early adulthood, while 12 months was chosen as an age representing approximately 50% of the lifespan for the C57BL/6 strain (22). Results demonstrate that adipocyte-derived AGT contributes to systemic AGT concentrations and blood pressure control. DEXA (Dual energy X-ray absorptiometry, LUNAR PIXImus, Janesville, WI, USA) at study endpoint. Blood was collected from anesthetized mice (ketamine/xylazine, 100/10 mg/kg, i.p.) just prior to study termination in tubes (4ºC) containing EDTA (0.2 M), centrifuged at 5,000 rpm for 10 min and plasmas were stored at -80°C. Tissues were snap frozen in liquid nitrogen and stored at -80°C.
MATERIALS AND METHODS

Generation
Measurement of fasting blood glucose (FBP) and glucose tolerance. Mice were fasted for 6 hours before quantification of blood glucose concentrations. For glucose tolerance tests, blood glucose was quantified at 0 min before injection of glucose solution (2 mg/kg body weight) and at 15, 30, 60 and 120 min after injection as described previously (19) .
Measurement of leptin and insulin in plasma.
Plasma concentrations of leptin and insulin were quantified in fed mice using a mouse leptin (Millipore, Billerica, MA) and mouse insulin Elisa kit (Millipore, Billerica, MA).
Measurement of systolic blood pressure (SBP)
. Systolic blood pressure was measured on conscious restrained mice via the Visitech BP-2000 tail cuff system (6) . Briefly, SBP was quantified for 5-10 days and measurements were taken at the approximate same time each day. Each cycle consisted of 10 preliminary tail cuff inflation/deflations for daily acclimation followed by 10 additional cycles that were recorded. Criteria for inclusion of measurements from individual mice were at least 4 out of 10 successful measurements with a standard deviation < 50 required for inclusion. 
RESULTS
Generation of mice with adipocyte AGT deficiency.
A transgenic construct including a neocassette flanked by 2 FRT sites (34 base pair FLP recombinase target) was transfected into embryonic stem cells (Fig. 1A) . ) .
To confirm effective and cell-selective deletion of AGT in adipocytes, DNA was genotyped ( Fig. 1B) and mRNA abundance of AGT was quantified in different tissues using RT-PCR (Fig. 1C) . Abundance of AGT mRNA was markedly and significantly reduced (by 90%) in RPF, EF, Subc and BAT ( mice was significantly reduced (by 72% on day 8; P < 0.01).
Adipocyte deficiency of AGT had no effect on body weight, fat mass, adipocyte size, or glucose homeostasis. Body weight increased with increasing age in male (Table 1 ) and female mice (Table 2 ) of each genotype, with no significant differences between genotypes. Fat mass increased markedly with age in male and female mice of each genotype (Table 1 , 2). Deficiency of AGT in adipocytes had no significant effect on fat mass at any age examined in male or female mice. Moreover, adipocytes from each genotype (12 months of age) had similar morphologic appearance (Fig. 3A) and were not significantly different in size or cell number (Fig. 3B, C There was a significant main effect of age (P < 0.001), genotype (P < 0.05), and gender (P < 0.05) on SBP (Fig. 5A ). Female mice of both genotypes exhibited significantly reduced SBP compared to age-matched males ( Fig. 5A ; P < 0.05). In addition, SBP was lower in 12 month old male and female mice, regardless of genotype, compared to 2 month old mice. Deficiency of AGT in adipocytes resulted in a significant reduction of SBP in male and female mice at 2 and 12 months of age ( Fig. 5A , P < 0.05).
There was a significant main effect of age (P < 0.01) and genotype (P < 0.001), but no effect of gender (P > 0.05) on plasma AGT concentrations (Fig. 5B) . Plasma AGT concentrations increased significantly with age (P < 0.001) in both male and female mice regardless of genotype. At 2 and 12 months of age, plasma AGT concentrations were significantly decreased in Agt aP2 male and female mice compared to control littermates ( Fig. 5B , P < 0.001).
Since adipose tissue mass increased markedly with increasing age in both genotypes (see Table 1 ), we correlated adipose tissue mass to SBP for all groups and factors (Fig. 6) . The linear regression model demonstrated a significant negative correlation between SBP and percent fat mass (estimated coefficient = -0.308, P < 0.05)
but not for AGT (estimated coefficient = 0.137, P > 0.05). The negative correlation between SBP and percent fat mass persisted when the analyses was restricted to mice with adipocyte AGT deficiency (P < 0.05), whereas no significant correlation was present between SBP and percent body fat in littermate controls (P > 0.05).
DISCUSSION
To our knowledge, this is the first report demonstrating that adipocyte-specific Previous studies demonstrated that whole body deficiency of AGT in mice resulted in non-detectable systemic concentrations of AGT and markedly reduced systolic blood pressure (35). However, these results did not identify the contribution of different AGT producing tissues to the profound effects of whole body AGT deficiency.
Of note, increased plasma AGT concentrations raised blood pressure in rats (14) , demonstrating the importance of systemic AGT for blood pressure control. Our results support a prominent role for adipose tissue as an important source for systemic AGT. Previous studies demonstrated that adipose and liver AGT mRNA abundance decreased in tissues from older compared to younger rats (1, 9) . In the present study,
AGT mRNA abundances were similar in liver and adipose tissue from wild type mice at age 2 and 12 months. Differences between results from this study with previous data demonstrating age-dependent reductions in adipose AGT mRNA abundance include the species examined (rats in previous studies versus mice in this study) and the ages of rodents under study (4 versus 12-16 week old rats in previous studies versus 8 and 52
week old mice in this study). In addition, since AGT mRNA abundance did not change with age in liver or adipose tissue from control mice, then reductions in systolic blood pressure with age in the present study were most likely unrelated to age-dependent changes in AGT mRNA expression.
In addition to profound effects of whole body AGT deficiency on plasma AGT 
